Skip to main content
Multiple Myeloma
Subgroup Analysis of the FORTE Study by Risk Categories of Carfilzomib-Based Induction/Consolidation with or without Autologous Transplant and Lenalidomide or Carfilzomib-Lenalidomide Maintenance
Read More
Multiple Myeloma
First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma
Read More
Multiple Myeloma
End-of-Study Analysis of the LYRA Study of Daratumumab Maintenance Therapy Following DARA plus CyBorD Induction Therapy in MM
Read More
Multiple Myeloma
MagnetisMM-1 Trial Results of Elranatamab in Patients with RRMM
Read More
Multiple Myeloma
Isatuximab Short-Duration, Fixed-Volume Infusion plus VRd for Patients with NDMM Ineligible or with No Intent for Immediate ASCT
Read More
Multiple Myeloma
Daratumumab plus Ixazomib, Lenalidomide, and Dexamethasone as Extended Induction and Consolidation Followed by Lenalidomide Maintenance in Standard-Risk Transplant-Eligible NDMM
Read More
Multiple Myeloma
Results of the Phase 2 HOVON 143 Study of Induction Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Intermediate-Fit Patients with NDMM
Read More
Multiple Myeloma
Management of Belantamab Mafodotin–Associated Corneal Events in Patients with RRMM
Read More
Multiple Myeloma
18-Month Analysis of the Phase 3 ANDROMEDA Study of Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain Amyloidosis
Read More
Multiple Myeloma
Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a BCMA x CD3 Bispecific Antibody, in RRMM
Read More
Page 62 of 200
Results 611 - 620 of 1993